Format

Send to

Choose Destination
See comment in PubMed Commons below
Drug Discov Today. 2011 Sep;16(17-18):831-9. doi: 10.1016/j.drudis.2011.07.006. Epub 2011 Jul 22.

Structure-based drug design to augment hit discovery.

Author information

1
Faculty of Science, Technology and Engineering, La Trobe University, Australia.

Abstract

Several technology-based strategies have been developed to address the significance of the two phases of drug discovery: hit identification and lead identification. Structure-based drug design (SBDD), a method that depends on possessing the knowledge of 3D structures of biological targets, is growing swiftly with the development of new technologies for searching potential ways to combat disease. The past decade has evidenced a threefold increase in the amount of software and tools in the online repositories. Herein, we review the in silico strategies and modules applied at the level of hit identification and confer the different challenges with possible solutions in enhancing the success rate of the 'hit-to-lead' phase that could eventually help the progress of SBDD in the drug discovery arena.

PMID:
21810482
DOI:
10.1016/j.drudis.2011.07.006
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center